Identifying Mediators of Exercise-induced Tumor Microenvironment Remodeling to Enhance Primary Chemotherapy Response (IMPROVE-Ovarian)

ClinicalTrials.gov ID: NCT07932106

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07932106. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Identifying Mediators of Exercise-induced Tumor Microenvironment Remodeling to Enhance Primary Chemotherapy Response

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this study is to (1) determine the feasibility and acceptability of a telehealth-delivered exercise intervention (including resistance and aerobic training) during neoadjuvant chemotherapy (NACT) for women with high-grade serous ovarian cancer (HGSOC) and to (2) determine the effect of exercise on changes in immune function, inflammation, and treatment response.

Study identification

NCT ID: NCT07932106
Recruitment status: Not yet recruiting
Study type: Interventional
Phase: Not applicable
Lead sponsor: University of Pittsburgh; Other
Enrollment: 20 participants

Conditions and interventions

Conditions

Interventions

Exercise Behavioral
Usual Care Behavioral

Behavioral

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 1, 2026 (Estimated)
Primary completion: Aug 31, 2027 (Estimated)
Completion: Sep 30, 2027 (Estimated)
Last update posted: Nov 12, 2026

2026 – 2027

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
UPMC Hillman Cancer Center	Pittsburgh	Pennsylvania	15213	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07932106, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 12, 2026 · Synced Nov 13, 2026